Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > TOP STORIES
TOP STORIES
-
REGULATORY Nichi-Iko’s Toyama Plant Gets Back Online as Suspension Order Lifted
April 6, 2021
-
REGULATORY Ex-PMDA Inspector Urges Improvements in Japanese Inspection Systems after GMP Scandals
April 5, 2021
-
BUSINESS Takeda/CSL-Led Alliance’s COVID-19 Plasma Therapy Fails in PIII
April 5, 2021
-
BUSINESS GSK Sees Promise in Antibody Therapy against Coronavirus Variants, Looking at Japan Rollout Too
April 2, 2021
-
BUSINESS Alinamin Aims for Growth via Retail Promotion, Full Entry into Asia: President
April 2, 2021
-
BUSINESS Sandoz Shooting for Top Foreign Player in Japan Generic Market by 2023
April 1, 2021
-
BUSINESS Japan Trials Get Underway for AstraZeneca’s COVID-19 Antibody Therapy
April 1, 2021
-
ORGANIZATION Generic Industry Group Requests Blanket Manufacturing Checkups for 39 Member Firms
March 31, 2021
-
BUSINESS Nafamostat Inhalation Drug Now in Clinic for COVID-19: Daiichi Sankyo
March 31, 2021
-
REGULATORY Japan Gives Up on Setting New Generic Target by March as Manufacturing Scandals Weigh
March 30, 2021
-
REGULATORY Japan to Wade Deeper into Generic Industry Revamp in New Pharma Vision, Due Out Summer
March 29, 2021
-
REGULATORY 35.6% of Pfizer Vaccine Recipients Developed Fevers after 2nd Shot, Higher Incidence in Women: MHLW
March 29, 2021
-
REGULATORY Nichi-Iko Starting Marketing Operations from March 29
March 29, 2021
-
ORGANIZATION Industry Group Poised for Pilot Rollout of E-Labeling App in April, Looks to Sales Reps for Popularization
March 26, 2021
-
BUSINESS Astellas Sees Growth Potential for “Rx+” as Future Bread-and-Butter Biz: EVP
March 26, 2021
-
REGULATORY Chuikyo OKs Appraisal Results for Kymriah, Trelegy; Downward Price Tweaks Expected
March 25, 2021
-
REGULATORY Nichi-Iko Plant Probed before Lifting of Biz Suspension Order
March 25, 2021
-
REGULATORY Japan Approves Incyte’s Pemazyre, Bayer’s Vitrakvi, Novartis’ Kesimpta, and More
March 24, 2021
-
REGULATORY Appraisal Results for Kymriah, Trelegy Up for Chuikyo Review on March 24; Price Cuts Likely
March 23, 2021
-
BUSINESS Japan Approves 3rd CAR-T Cell Therapy, Celgene’s Breyanzi
March 23, 2021
ページ
Japan’s pharmaceutical industry could be on the verge of gaining a stronger voice in the Central Social Insurance Medical Council…
Let’s face it: in today’s world, changing jobs is a normal part of a successful career. But if it’s so normal, why does it feel so hard? For many people, the idea of leaving their current role brings a heavy…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…